Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.78 |
| ▸ | MAPT | P10636 | 3/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | RAB9A | P51151 | 2/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | CA12 | O43570 | 1/20 | 0.58 |
| ▸ | CA1 | P00915 | 1/20 | 0.58 |
| ▸ | CA2 | P00918 | 1/20 | 0.58 |
| ▸ | CA9 | Q16790 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.57 |
| ▸ | MTOR | P42345 | 2/20 | 0.57 |
| ▸ | BAZ1A | Q9NRL2 | 1/20 | 0.57 |
| ▸ | KIF11 | P52732 | 1/20 | 0.56 |
| ▸ | TGM2 | P21980 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | RORC | P51449 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28729179 | 0.88 | EPHX2 (1.00) | EPHX2MAPTKMT2AMEN1RAB9A | |
| SCHEMBL11003408 | 0.88 | EPHX2 (1.00) | EPHX2MAPTKMT2AMEN1RAB9A | |
| SCHEMBL10155599 | 0.83 | ALDH1A1 (0.78) | EPHX2MAPTKMT2ARAB9AALDH1A1 | |
| SCHEMBL16946637 | 0.83 | EPHX2 (0.81) | EPHX2MAPTKMT2AMEN1RAB9A | |
| SCHEMBL10201044 | 0.82 | NPC1 (0.68) | EPHX2MAPTKMT2AMEN1RAB9A | |
| SCHEMBL12491371 | 0.82 | EPHX2 (0.81) | EPHX2MAPTKMT2AMEN1RAB9A | |
| SCHEMBL19204183 | 0.82 | SMN1; SMN2 (0.54) | EPHX2MAPTKMT2AMEN1RAB9A | |
| SCHEMBL15946352 | 0.81 | EPHX2 (0.72) | EPHX2MAPTKMT2AMEN1RAB9A | |
| SCHEMBL7951394 | 0.81 | MAPT (1.00) | EPHX2MAPTKMT2AMEN1RAB9A | |
| SCHEMBL5742980 | 0.81 | EPHX2 (0.78) | EPHX2MAPTKMT2AMEN1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022003712-A1 | QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2022-01-06 | — | — | WO | disclosed |
| WO-2016012333-A1 | PESTICIDAL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2016-01-28 | — | — | WO | disclosed |
| US-7989422-B2 | Antibacterial agents | ALCHEMIA LIMITED (AU) | 2011-08-02 | — | — | US | disclosed |
| US-20090048186-A1 | Monosaccharide Derivatives as Anti-Inflammatory and/or Anti-Cancer Agents | RANBAXY LABORATORIES LIMITED (IN) | 2009-02-19 | — | — | US | disclosed |
| US-20090048186-A1 | Monosaccharide Derivatives as Anti-Inflammatory and/or Anti-Cancer Agents | RANBAXY LABORATORIES LIMITED (IN) | 2009-02-19 | — | — | US | disclosed |
| US-20090023669-A1 | Antibacterial Agents | ALCHEMIA LIMITED (AU) | 2009-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048186-A1 | Monosaccharide Derivatives as Anti-Inflammatory and/or Anti-Cancer Agents | HLA-DRB1, MUC1, ASGR1 | EPHX2 3999/4885MAPT 1151/4885KMT2A 4199/4885 |
| US-20090023669-A1 | Antibacterial Agents | MRPL21, FUT6, FUT5 | EPHX2 4199/4885MAPT 4853/4885KMT2A 4563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.